The effect of combination antiretroviral therapy on CD5 B‐ cells, B‐cell activation and hypergammaglobulinaemia in HIV‐1‐infected patients
Authors:
- 7 September 2005
- journal article
- Published by Wiley in HIV Medicine
- Vol. 6 (5) , 307-312
Abstract
Objectives: This study assessed B‐cell activation, CD5 B‐cells and circulating immunoglobulin levels in HIV‐infected patients treated with combination antiretroviral therapy (CART).Methods: Measurement of plasma immunoglobulin levels and electrophoresis of plasma proteins, and analyses of total numbers of B‐cells and B‐cells expressing CD38 and CD5 in whole blood, were undertaken in 47 consecutive HIV‐1‐infected patients attending an out‐patient clinic.Results: All HIV‐infected patients had similar percentages and numbers of B‐cells. Proportions of CD5 B‐cells in all HIV‐infected patients were significantly lower than those in HIV‐negative controls. Aviraemic HIV‐infected patients on CART had lower percentages of CD5, CD38 and CD5 CD38 B‐cell subsets and lower plasma levels of immunoglobulin G (IgG) and immunoglobulin A (IgA) than viraemic HIV‐infected patients (untreated or on CART). However, 33–37% of aviraemic HIV‐infected patients had IgG and IgA levels above the 95th percentile of the normal range defined in HIV‐seronegative donors. In aviraemic HIV‐infected patients, plasma IgA levels correlated only with proportions of activated (CD38) B‐cells. IgG levels did not correlate with the proportions of B‐cell subsets or any marker of HIV disease activity. Monoclonal immunoglobulins were not detected in any plasma sample.Conclusions: Aviraemic HIV‐infected patients on CART have lower plasma levels of IgG and IgA than viraemic HIV‐infected patients, but levels are often above the normal range. CD5 B‐cell numbers are depressed, so these cells are unlikely to contribute to hypergammaglobulinaemia in HIV‐infected patients.Keywords
This publication has 20 references indexed in Scilit:
- Selective CD27 (Memory) B Cell Reduction and Characteristic B Cell Alteration in Drug-Naive and HAART-Treated HIV Type 1-Infected PatientsAIDS Research and Human Retroviruses, 2004
- T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral TherapyThe Journal of Infectious Diseases, 2003
- Human Immunoglobulin M Memory B Cells Controlling Streptococcus pneumoniae Infections Are Generated in the SpleenJournal of Experimental Medicine, 2003
- Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 productionBlood, 2002
- Brief Communication: Immune Activation in Patients Infected with HIV Type 1 and Maintaining Suppression of Viral Replication by Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 2002
- Origins and Functions of B-1 Cells with Notes on the Role of CD5Annual Review of Immunology, 2002
- Potent Antiretroviral Therapy Initiates Normalization of Hypergammaglobulinemia and a Decline in HIV Type 1-Specific Antibody ResponsesAIDS Research and Human Retroviruses, 2001
- CD5-positive B cells in healthy elderly humans are a polyclonal B cell populationEuropean Journal of Immunology, 2000
- Anti-phospholipid antibodies and CD5+ B cells in HIV infectionClinical and Experimental Immunology, 1999
- Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1983